0001077183-24-000075.txt : 20240514
0001077183-24-000075.hdr.sgml : 20240514
20240514213920
ACCESSION NUMBER: 0001077183-24-000075
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240511
FILED AS OF DATE: 20240514
DATE AS OF CHANGE: 20240514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Christopher M
CENTRAL INDEX KEY: 0001436707
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35756
FILM NUMBER: 24946821
MAIL ADDRESS:
STREET 1: 125 CONSTITUTION DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEOGENOMICS INC
CENTRAL INDEX KEY: 0001077183
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 742897368
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9490 NEOGENOMICS WAY
CITY: FORT MYERS
STATE: FL
ZIP: 33912
BUSINESS PHONE: 2397680600
MAIL ADDRESS:
STREET 1: 9490 NEOGENOMICS WAY
CITY: FORT MYERS
STATE: FL
ZIP: 33912
FORMER COMPANY:
FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC
DATE OF NAME CHANGE: 19990120
4
1
wk-form4_1715737144.xml
FORM 4
X0508
4
2024-05-11
0
0001077183
NEOGENOMICS INC
NEO
0001436707
Smith Christopher M
9490 NEOGENOMICS WAY
FORT MYERS
FL
33912
0
1
0
0
Chief Executive Officer
0
Common Stock
2024-05-11
4
M
0
48063
0
A
650282
D
Common Stock
2024-05-11
4
F
0
18913
14.86
D
631369
D
Common Stock
2024-05-11
4
M
0
48063
0
A
679432
D
Restricted Stock Unit
0
2024-05-11
4
M
0
48063
0
D
Common Stock
48063
96127
D
Stock Option (Right to Buy)
12.62
2029-08-15
Common Stock
694444
694444
D
Stock Option (Right to Buy)
19.65
2030-05-11
Common Stock
269841
269841
D
Performance Stock Unit
0
2026-05-11
Common Stock
144190
144190
D
Stock Option (Right to Buy)
16.45
2034-02-23
Common Stock
287940
287940
D
Restricted Stock Unit
0
Common Stock
172239
172239
D
Performance Stock Unit
0
2027-02-23
Common Stock
172240
172240
D
Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
Once vested, the shares of common stock are not subject to expiration.
On August 15, 2022, Mr. Smith was granted 694,444 stock options. These options vest ratably over the first four anniversary dates of the grant date.
On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date.
On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
On February 23, 2024, Mr. Smith was granted 287,940 stock options. These options vest ratably over the first three anniversary dates of the grant date.
On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
On February 23, 2024, Mr. Smith was granted 172,240 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 258,360. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
/s/ Ali Olivo, Attorney-in-Fact
2024-05-14